Brief: Adaptimmune Therapeutics & Gsk Entered Into Termination & Transfer Agreement - SEC Filing

Adaptimmune Therapeutics

11/04/2023 13:21

April 11 (Reuters) - Adaptimmune Therapeutics PLC
 ADAP.O :
    * ADAPTIMMUNE THERAPEUTICS PLC: ON APRIL 6, CO AND GSK
ENTERED
INTO A TERMINATION AND TRANSFER AGREEMENT - SEC FILING
    * ADAPTIMMUNE THERAPEUTICS: UNDER TERMINATION AND TRANSFER
DEAL,
GSK AGREED TO PAY CO UPFRONT AND MILESTONE PAYMENTS TOTALING £30
MILLION
    * ADAPTIMMUNE THERAPEUTICS PLC: CO, GSK AGREED TO DETAILED
PLANS
UNDER WHICH GSK WILL REVERT TO ADAPTIMMUNE PRAME AND NY-ESO CELL
THERAPY PROGRAMS
    * ADAPTIMMUNE THERAPEUTICS PLC: PLANS TO BE IND-READY IN
2023 WITH
A PRAME TARGETED TCR T-CELL THERAPY
    * ADAPTIMMUNE THERAPEUTICS: CO, GSK TO ENSURE CONTINUITY FOR
PATIENTS IN ONGOING TRIALS FOR LETE-CEL, NEXT GENERATION TCR
T-CELLS TARGETING NY-ESO

Source text for Eikon:  ID: 
Further company coverage:  ADAP.O 

 ((Reuters.Briefs@thomsonreuters.com;))